Shares of Amarin (AMRN -2.2%) slip out of the gate this morning, possibly on cautious comments...

Shares of Amarin (AMRN -2.2%) slip out of the gate this morning, possibly on cautious comments out of Summer Street. The firm says Vascepa doesn't have data to support superiority compared to other fish oils such as Lovaza by Glaxo SmithKline (GSK -0.6%) which third party payers are likely to favor.
From other sites
Comments (7)
  • Guest2115
    , contributor
    Comments (14) | Send Message
    i strongly disagree - the lowering of LDL alone is an important and distinguishing benefit of Vascepa as opposed to the rise in LDL caused by Lovaza
    5 Dec 2012, 10:40 AM Reply Like
  • Guest2115
    , contributor
    Comments (14) | Send Message
    I am a pharma veteran with more than 40 years of experience
    5 Dec 2012, 10:41 AM Reply Like
  • bnw43762
    , contributor
    Comments (13) | Send Message
    Summer Street must be wanting to get some shares on the cheap, because everyone knows the Amarin's fish oil (all EPA) is far superior to Lovaza. I took Lovaza when it first came out and before my doctors even knew about the potential to increase LDL. My LDL skyrocket to the high 200's. Once I discontinued it, they returned to normal. I take a OTC fish oil that is 80% EPA and my Try's and LDL are normal and I don't need to take a statin anymore. What doctor, with Vascepa available, for a patient for risk of CVD, would write a script for Lovaza and put their patient at increased risk for an MI or stroke? If you can find a doctor willing to do this, change doctors!!
    5 Dec 2012, 11:03 AM Reply Like
  • Hoang6
    , contributor
    Comments (358) | Send Message
    AMRN slips because the whole market is down today, not because of the cautious comments or any other bs. Stocks may be manipulated, but smart investors dont dump stocks just because of random news.
    5 Dec 2012, 11:11 AM Reply Like
  • biogiant
    , contributor
    Comments (22) | Send Message
    Totally laughable!
    5 Dec 2012, 12:34 PM Reply Like
  • Rob Chanock
    , contributor
    Comments (253) | Send Message
    They absolutely do have the data to support it-witness the LDL differentiation for one. The only question mark appears to be the FDA decision on NCE which has some significance but even that is not a deal breaker. Patience with this stock could reap substantial rewards.
    5 Dec 2012, 02:25 PM Reply Like
  • wiesemc
    , contributor
    Comments (558) | Send Message
    Something smells fishy with Summer Street's analysis. Get it.
    5 Dec 2012, 10:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs